Chest Medicine
Review: Histiocytic disorders.
24 Jan, 2022 | 08:02h | UTCHistiocytic disorders – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Histiocytic disorders (if the link is paywalled, try this one)
Commentary on Twitter
Haemophagocytic lympho #histiocytosis is a syndrome of extreme #immune activation; common manifestations include involvement of the central nervous system, hepatitis or acute liver failure.https://t.co/heXWqru8wW pic.twitter.com/1A0SFIhkwR
— Nature Reviews Disease Primers (@DiseasePrimers) January 21, 2022
Opinion: COVID-19 will continue but the end of the pandemic is near.
21 Jan, 2022 | 10:16h | UTCCOVID-19 will continue but the end of the pandemic is near – The Lancet
Commentary on Twitter
.@IHME_UW's Chris Murray predicting the end of the pandemic is nigh
"More than 50% of the world will have been infected with omicron …[by] the end of March, 2022"
"After the omicron wave, COVID-19 will return but the pandemic will not."https://t.co/9NSw8lZuUe @TheLancet— Eric Topol (@EricTopol) January 20, 2022
Review: Postdischarge Evaluation for Individuals Hospitalized with COVID-19.
21 Jan, 2022 | 10:08h | UTCPostdischarge Evaluation for Individuals Hospitalized with COVID-19 – Southern Medical Journal
Europe considers new COVID-19 strategy: Accepting the virus.
21 Jan, 2022 | 10:13h | UTCEurope considers new COVID-19 strategy: Accepting the virus – Associated Press
ATS Guideline: Outpatient respiratory management of infants, children, and adolescents with post-prematurity respiratory disease.
21 Jan, 2022 | 09:55h | UTC
Booster longevity: Data reveals how long a third shot protects.
20 Jan, 2022 | 09:33h | UTCBooster longevity: Data reveals how long a third shot protects – NPR
Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency
A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.
20 Jan, 2022 | 09:30h | UTCEffectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine
Commentary on Twitter
In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW
— NEJM (@NEJM) January 19, 2022
Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.
20 Jan, 2022 | 09:25h | UTCFluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal
Related:
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Milder disease with Omicron: is it the virus or the pre-existing immunity?
20 Jan, 2022 | 09:28h | UTC
How does Omicron spread so fast? A high viral load isn’t the answer – “Data on viral levels point to immune evasion as a cause of the variant’s transmissibility”.
20 Jan, 2022 | 09:27h | UTCHow does Omicron spread so fast? A high viral load isn’t the answer – Nature
Review: Evaluating the patient with a pulmonary nodule.
20 Jan, 2022 | 08:56h | UTCEvaluating the Patient With a Pulmonary Nodule: A Review – JAMA (free for a limited period)
Author Interview: Evaluation and Management of Patients With Pulmonary Nodules
COVID-19 testing infographics.
19 Jan, 2022 | 08:59h | UTCCOVID-19 testing infographics – British Society for Immunology
Commentary on Twitter
It’s important to understand #COVID19 testing so everyone can make informed decisions about their health ℹ🦠
Our infographics & blog have been updated with the latest information & guidance so you can find out what different tests mean for you 👉https://t.co/7a5Ul6tEZn pic.twitter.com/mUzdZc13aa
— British Society for Immunology (@britsocimm) January 17, 2022
RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.
19 Jan, 2022 | 08:56h | UTCEditorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA
Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay
Fact check: The theory that SARS-CoV-2 is becoming milder.
19 Jan, 2022 | 08:44h | UTCFact check: The theory that SARS-CoV-2 is becoming milder – NPR
Systematic Review: Intermittent prophylactic antibiotics for bronchiectasis.
19 Jan, 2022 | 08:33h | UTCIntermittent prophylactic antibiotics for bronchiectasis – Cochrane Library
Summary: Long term antibiotics taken at regular intervals by people with bronchiectasis – Cochrane Library
Practical guide to cardiopulmonary exercise testing in adults.
19 Jan, 2022 | 08:26h | UTCPractical guide to cardiopulmonary exercise testing in adults – Respiratory Research
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
18 Jan, 2022 | 09:59h | UTCSee also:
Israeli trial, world’s first, finds 4th dose ‘not good enough’ against Omicron – The Times of Israel
Israel study: 4th vaccine shows limited results with omicron – MedicalXpress
COVID-19 updated evidence: a Cochrane round-up.
18 Jan, 2022 | 09:53h | UTCCOVID-19 evidence: a Cochrane round-up – Cochrane Library
Time to upgrade from cloth and surgical masks to respirators? Your questions answered.
18 Jan, 2022 | 09:48h | UTCSee also: The CDC updated its mask guidelines. What to know about ‘the highest level of protection’ – CNN
Study raises doubts about rapid Covid tests’ reliability in early days after infection.
18 Jan, 2022 | 09:51h | UTCStudy raises doubts about rapid Covid tests’ reliability in early days after infection – STAT
Original Article (preprint): Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series – medRxiv
Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.
18 Jan, 2022 | 09:41h | UTC
WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.
17 Jan, 2022 | 00:48h | UTCNews release: WHO recommends two new drugs to treat COVID-19 – World Health Organization
Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ
Commentaries:
Commentary on Twitter (thread – click for more)
WHO has also conditionally recommended the use of sotrovimab for treating mild or moderate #COVID19 in patients who are at high risk of hospitalization: patients who are older, immunocompromised, with underlying conditions & those unvaccinated https://t.co/UAc21Wgxbl https://t.co/Z39mSKrOv5
— World Health Organization (WHO) (@WHO) January 14, 2022
ASCO Guideline: Management of stage III non–small-cell lung cancer.
18 Jan, 2022 | 09:12h | UTCManagement of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology
Viewpoint: COVID-19 therapeutics for nonhospitalized patients.
17 Jan, 2022 | 00:31h | UTCCOVID-19 Therapeutics for Nonhospitalized Patients – JAMA
Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA
New UK Guidance: Self-isolation for those with COVID-19 can end after 5 full days following 2 negative rapid lateral flow tests – “The default self-isolation period continues to be 10 days, and you may only leave self-isolation early if you have taken 2 rapid lateral flow tests and do not have a temperature in line with guidance”.
14 Jan, 2022 | 08:48h | UTC
Commentary on Twitter (thread – click for more)
Self-isolation period for people infected with COVID in England will be reduced to 5 days from Monday 17 Jan. But it's conditional: 2 NEGATIVE tests on days 5 & 6, & no symptoms, & not in certain high risk situations e.g. working with vulnerable people
1/https://t.co/HLxlIbpbkR— Andrew Lee is heading to @andrewleedr.bsky.social (@andrewleedr) January 13, 2022